Navigate through the complicated landscape of intellectual property and generics

April 5, 2013 - PRLog -- FirstWordPharma.com recently reported Pfizer warned India's "protectionist intellectual property regime" is hindering investment in the country. This happened after India's patent office revoked Pfizer's patent covering the cancer drug Sutent (Sunitinib), it was also indicated that India has started the process of issuing compulsory licenses which "will destroy the market for innovative pharmaceuticals in India". Therefore it is imperative to have an understanding to the principles behind Intellectual Property (IP) as it can cause serious damage to generic launch plans and their chances of success.

Under the guidance of Interpharm this masterclass will help you to navigate the complicated landscape of intellectual property and generics. IP issues can affect generic development, registration and launch and making mistakes due to a lack of knowledge can work out very expensive. Generic companies are also increasingly aggressive in their use of patents against each other to gain advantages, which has led to generic wars.

"... India's "protectionist intellectual property regime" is hindering investment in the country"

-END-

Contact Jonathan Collins on +44 (0) 20 7827 6734 | jcollins@smi-online.co.uk